Darexaban
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Darexaban
- DrugBank Accession Number
- DB12289
- Background
Darexaban has been used in trials studying the prevention and basic science of Japanese, Caucasian, Thromboembolism, Pharmacodynamics, and Pharmacokinetics, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 474.561
Monoisotopic: 474.226705462 - Chemical Formula
- C27H30N4O4
- Synonyms
- Darexaban
- External IDs
- YM-150
- YM150
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Darexaban. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Darexaban. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Darexaban is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Darexaban. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Darexaban. - Food Interactions
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Darexaban Maleate 03RTP2436R 365462-24-4 WHMPMUVISXATBH-BTJKTKAUSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzanilides. These are aromatic compounds containing an anilide group in which the carboxamide group is substituted with a benzene ring. They have the general structure RNC(=O)R', where R,R'= benzene.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Anilides
- Direct Parent
- Benzanilides
- Alternative Parents
- Aminobenzoic acids and derivatives / Benzamides / Aniline and substituted anilines / Anisoles / Benzoyl derivatives / Dialkylarylamines / Methoxybenzenes / Phenoxy compounds / 1-hydroxy-2-unsubstituted benzenoids / 1,4-diazepanes show 8 more
- Substituents
- 1,4-diazepane / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / Alkyl aryl ether / Amine / Amino acid or derivatives / Aminobenzoic acid or derivatives / Aniline or substituted anilines / Anisole / Aromatic heteromonocyclic compound show 25 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- KF322K101S
- CAS number
- 365462-23-3
- InChI Key
- IJNIQYINMSGIPS-UHFFFAOYSA-N
- InChI
- InChI=1S/C27H30N4O4/c1-30-15-4-16-31(18-17-30)21-11-7-19(8-12-21)27(34)29-25-23(5-3-6-24(25)32)28-26(33)20-9-13-22(35-2)14-10-20/h3,5-14,32H,4,15-18H2,1-2H3,(H,28,33)(H,29,34)
- IUPAC Name
- N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4-(4-methyl-1,4-diazepan-1-yl)benzamide
- SMILES
- COC1=CC=C(C=C1)C(=O)NC1=C(NC(=O)C2=CC=C(C=C2)N2CCCN(C)CC2)C(O)=CC=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 9912771
- PubChem Substance
- 347828557
- ChemSpider
- 8088422
- BindingDB
- 50358252
- ChEMBL
- CHEMBL1922235
- ZINC
- ZINC000070647134
- Wikipedia
- Darexaban
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Prevention Venous Thromboembolism 4 2 Completed Prevention Acute Coronary Syndrome (ACS) 1 2 Completed Prevention Arthroplasties, Replacement, Knee 1 2 Completed Prevention Atrial Fibrillation 2 2 Completed Prevention Thromboembolism 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0291 mg/mL ALOGPS logP 4.03 ALOGPS logP 2.96 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 8.32 Chemaxon pKa (Strongest Basic) 8.95 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 94.14 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 140.91 m3·mol-1 Chemaxon Polarizability 52.36 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0900000000-ef0759aa6d18e159792a Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-00di-0300900000-52d73de07ba91b689f21 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-052r-0900100000-51a25e12d765a8dd07c6 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-00rj-1417900000-bb0ba4af197055c07d72 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0aor-2930500000-73ecd4632b86834438f5 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-054o-6121900000-34dcd4efc2508e345b5b Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 207.4847 predictedDeepCCS 1.0 (2019) [M+H]+ 209.88026 predictedDeepCCS 1.0 (2019) [M+Na]+ 215.79279 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 21:50 / Updated at February 21, 2021 18:53